Induced Pluripotent Stem Cells in Disease Modelling and Regeneration

Author(s):  
Burcu Talug ◽  
Zeynep Tokcaer-Keskin
2012 ◽  
Vol 120 (1) ◽  
pp. 103-111 ◽  
Author(s):  
Lezanne Ooi ◽  
Kuldip Sidhu ◽  
Anne Poljak ◽  
Greg Sutherland ◽  
Michael D. O’Connor ◽  
...  

Cells ◽  
2021 ◽  
Vol 10 (9) ◽  
pp. 2319
Author(s):  
Mourad A. M. Aboul-Soud ◽  
Alhusain J. Alzahrani ◽  
Amer Mahmoud

The discovery of induced pluripotent stem cells (iPSCs) has made an invaluable contribution to the field of regenerative medicine, paving way for identifying the true potential of human embryonic stem cells (ESCs). Since the controversy around ethicality of ESCs continue to be debated, iPSCs have been used to circumvent the process around destruction of the human embryo. The use of iPSCs have transformed biological research, wherein increasing number of studies are documenting nuclear reprogramming strategies to make them beneficial models for drug screening as well as disease modelling. The flexibility around the use of iPSCs include compatibility to non-invasive harvesting, and ability to source from patients with rare diseases. iPSCs have been widely used in cardiac disease modelling, studying inherited arrhythmias, neural disorders including Alzheimer’s disease, liver disease, and spinal cord injury. Extensive research around identifying factors that are involved in maintaining the identity of ESCs during induction of pluripotency in somatic cells is undertaken. The focus of the current review is to detail all the clinical translation research around iPSCs and the strength of its ever-growing potential in the clinical space.


2013 ◽  
Vol 23 (1) ◽  
pp. 281-281
Author(s):  
G. Tiscornia ◽  
E. Lorenzo Vivas ◽  
L. Matalonga ◽  
I. Berniakovich ◽  
M. Barragan Monasterio ◽  
...  

2012 ◽  
Vol 22 (4) ◽  
pp. 633-645 ◽  
Author(s):  
Gustavo Tiscornia ◽  
Erika Lorenzo Vivas ◽  
Leslie Matalonga ◽  
Ina Berniakovich ◽  
Montserrat Barragán Monasterio ◽  
...  

Amyloid ◽  
2018 ◽  
Vol 25 (3) ◽  
pp. 148-155 ◽  
Author(s):  
Richard M. Giadone ◽  
Jessica D. Rosarda ◽  
Prithvi Reddy Akepati ◽  
Arianne C. Thomas ◽  
Batbold Boldbaatar ◽  
...  

2011 ◽  
Vol 10 (12) ◽  
pp. 915-929 ◽  
Author(s):  
Marica Grskovic ◽  
Ashkan Javaherian ◽  
Berta Strulovici ◽  
George Q. Daley

2020 ◽  
Vol 15 ◽  
Author(s):  
Shu Nakao ◽  
Dai Ihara ◽  
Koji Hasegawa ◽  
Teruhisa Kawamura

Induced pluripotent stem cells (iPSCs) are derived from reprogrammed somatic cells by the introduction of defined transcription factors. They are characterised by a capacity for self-renewal and pluripotency. Human (h)iPSCs are expected to be used extensively for disease modelling, drug screening and regenerative medicine. Obtaining cardiac tissue from patients with mutations for genetic studies and functional analyses is a highly invasive procedure. In contrast, disease-specific hiPSCs are derived from the somatic cells of patients with specific genetic mutations responsible for disease phenotypes. These disease-specific hiPSCs are a better tool for studies of the pathophysiology and cellular responses to therapeutic agents. This article focuses on the current understanding, limitations and future direction of disease-specific hiPSC-derived cardiomyocytes for further applications.


Sign in / Sign up

Export Citation Format

Share Document